Gates Package — page 249

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Dewpoint Therapeutics Marc Charette, Ph.D. Program Director, Division of Cardiovascular Diseases National Heart, Lung, and Blood Institute, NIH Tomas Cihlar, Ph.D. Vice President and Head of Virology Gilead Sciences, Inc. Christine Colvis, Ph.D. (Co-Chair) Director, Drug Development Partnership Programs National Center for Advancing Translational Sciences, NIH Michael Diamond, M.D., Ph.D. Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology Washington University School of Medicine in St. Louis Ken Duncan, Ph.D. Deputy Director, Discovery -- Therapeutics Bill & Melinda Gates Foundation Prabhavathi Fernandes, Ph.D. Chair, Scientific Advisory Committee, Global Antibiotic Research and Development Partnership; Chair, National Biodefense Science Board Joshua Fessel, M.D., Ph.D. Program Director, Lung Vascular Biology Program, Division of Lung Disease National Heart, Lung, and Blood Institute, NIH Clint Florence, Ph.D. Program Officer, Research Resource Section, OBRR, DMID National Institute of Allergy and Infectious Diseases, NIH Greg Gatto, Ph.D. Drug Development Regulatory Project Leader RTI International Jay Grobler, Ph.D. Executive Director, Infectious Disease and Vaccines Merck & Co., Inc. Nancy Haigwood, Ph.D. Director and Professor, Oregon National Primate Research Center Oregon Health & Science University Judith Hewitt, Ph.D. Deputy Director, Office of Biodefense, Research Resources and Translational Research